Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 4

Featuring an interview with Prof Karim Fizazi, including the following topics: Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00) Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37) Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47) Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43) Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51) Role of intermittent therapy in the treatment of prostate cancer (38:48) Treatment intensification approaches in prostate cancer (41:38) Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)

Featuring perspectives from Prof Susana Banerjee, including the following topics: Overview of the biology and treatment of low-grade serous ovarian cancer (0:00) Mechanism of action of avutometinib/defactinib (10:16) RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian cancer (14:32) Ongoing clinical trials in low-grade serous ovarian cancer (27:57)

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics: Introduction and Overview of Bispecific Antibodies in the Clinic (0:00) Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58) Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40) Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50) Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39) Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50) Case: A woman in her early 70s with FL receives epcoritamab (1:26:38) Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28) Case: A woman in her late 40s with FL receives epcoritamab (1:38:33) Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)

Featuring a slide presentation from Dr Julia Rotow, including the following topics: Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00) Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12) Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59) Clinician insights about the potential role of ivonescimab in the front-line setting (12:02) Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01) Key findings from the Phase III HARMONi-A and HARMONi studies (16:07) Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)

Featuring perspectives from Dr Catherine C Coombs, including the following topics: Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00) Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42) Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50) Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)